Index
Module 19 • Pulmonology
Pulmonary Disorders II
55%
Data Tables
Pulmonary Disorders II
Zachary R. Smith ~3 min read Module 19 of 20
24
/ 44

Pulmonary Disorders II

5

Seasonal weather changes

6

Poor adherence to inhaled corticosteroids

C.Mortality Risk Factors (Multidiscip Respir Med. 2016;11:37; Global Initiative for Asthma 2024)
1

History of near-fatal asthma (e.g., requiring MV)

2Hospitalization or ED visit for asthma in the past year
3

Active use of oral corticosteroids or completion of recent course for asthma

4

Not currently using inhaled corticosteroids

5

Use of more than one canister of short-acting Ξ²-agonists (SABAs) per month

6

Poor adherence to inhaled corticosteroid containing asthma medications and/or poor adherence to

asthma action plan

7

History of psychiatric disease or psychosocial problems

8

Food allergy in a patient with asthma

9

Social history that includes major psychosocial problems or psychiatric illness

10Food allergies
11Comorbidities including pneumonia, diabetes, and arrhythmias
D.Social Determinants of Health in patients with asthma (Ann Allergy Asthma Immunol 2022;128:5-11)
1

Black and Latinx Americans have higher asthma prevalence and asthma-related morbidity than other

populations.

2Adults with a household income < $50,000 had a 1.6 times higher rate of asthma treatment failure and

2 times higher rate of asthma exacerbations compared with those with a household income >=$50,000.

3

The impacts of long-term stress, health care access, environmental factors, education level, and food

accessibility on disease prevalence and management in patients with asthma are active areas of research.

E.COVID-19 (SARS-CoV-2) and Asthma (GINA 2024)
1

Patients with well-controlled asthma do not appear to be at increased risk of infection or mortality due

to SARS-CoV-2.

2However, patients who acquire COVID-19 with poorly controlled asthma (eg, recent need of oral

corticosteroids) are at higher risk of hospitalization for severe disease.

3

Both GINA and the Centers for Disease Control and Prevention recommend that patients receive

vaccination against COVID-19 including boosters if applicable.

4

If patients are receiving biologics for their severe asthma, it is not recommended to give the first dose

of a biologic agent and the COVID-19 vaccine on the same day.

F.

Alternative Causes (mimic asthma exacerbation) (N Engl J Med. 2023;389(11):1023-1031)

1

Upper airway: Vocal cord dysfunction, anaphylaxis, laryngeal stenosis

2Central airway: Tracheomalacia, tracheal stenosis mucus plugging
3

Lower airway: Bronchiolitis, COPD, valvular heart disease, diastolic heart dysfunction

G.ABG Assessment
1

Patients with acute severe asthma initially experience a respiratory alkalosis.

2As respiratory status worsens, arterial carbon dioxide increases (patient exhaustion, inadequate alveolar

ventilation and/or an increase in physiologic dead space), leading to respiratory acidosis. A Pao2 less

than 60 mm Hg with or without a Paco2 greater than 45 mm Hg may also indicate respiratory failure.

3

Metabolic (lactic) acidosis may coexist. Lactate production presumably stems from the use of high-dose

Ξ²-agonists, increased work of breathing resulting in anaerobic metabolism of the ventilatory muscles,

and tissue hypoxia.

HD Video Explanation β€” Synchronized with PDF
Starts at: minute 23 Open on YouTube